ACTICOR BIOTECH: Acticor Biotech Announces Its 2021 Full-year Financial Results and Gives an Update on Its Clinical Development
Successful IPO on Euronext Growth in Paris Cash position of €11.3 million at 31 December 2021 Promising clinical results with the continuing development of glenzocimab for use in stroke Regulatory